Haratani K, et al. - This study aimed to investigate the association of immune-related adverse events (irAEs) with nivolumab efficacy in non–small-cell lung cancer (NSCLC). In patients with advanced or recurrent NSCLC, development of irAEs seemed associated with survival outcome of nivolumab treatment.